STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Woodline Discloses 2.55M Shares of SGMT; Schedule 13G Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Woodline Partners LP disclosed beneficial ownership of 2,552,536 shares of Sagimet Biosciences Series A common stock, representing approximately 8.3% of the outstanding class. The shares are directly held by Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, and the reporting page shows Woodline Partners has sole voting and dispositive power over these shares.

The filing was made on Schedule 13G and includes a certification that the securities were acquired and are held in the ordinary course of business and were not purchased to change or influence control of the issuer. The percentage is calculated using an aggregate share base of about 30,674,855 shares reported in the company’s quarterly report for the period ended March 31, 2025.

Positive

  • Material disclosed stake: Reporting of 2,552,536 shares (~8.3%) is a clear, material ownership disclosure
  • Clear control authority: Reporting person states sole voting and dispositive power over the shares
  • Schedule 13G certification: Filing includes a certification that the shares were acquired and are held in the ordinary course of business and not to influence control

Negative

  • None.

Insights

Woodline holds a material passive stake ~8.3%, disclosed via Schedule 13G; no stated intent to seek control.

Holding 2,552,536 shares, equal to roughly 8.3% of the reported ~30.7 million share class, is large enough to be material for investors and can affect float and voting outcomes. The Schedule 13G form and the included certification indicate Woodline views this as a passive, ordinary-course position rather than an activist or control-seeking stake. For analysts, the key points are the stake size, sole voting/dispositive power, and the public acknowledgment that the position is not intended to influence control.

An >5% disclosure is governance-relevant; Schedule 13G signals passive ownership but still warrants monitoring for voting impact.

From a governance perspective, a declared 8.3% holder with sole voting authority can be influential on shareholder votes, even if the filer asserts passive intent. The filing identifies Woodline Partners as the investment adviser to the fund that directly holds the shares and explicitly states the securities are held in the ordinary course of business and not to influence control. While Schedule 13G filings typically reflect non-activist positions, boards and investors commonly note such stakes because they change the ownership landscape and could mobilize in future corporate actions.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Woodline Partners LP
Signature:/s/ Erin Mullen
Name/Title:Erin Mullen, General Counsel & Chief Compliance Officer
Date:08/14/2025

FAQ

How many Sagimet (SGMT) shares does Woodline Partners report owning?

Woodline Partners reports beneficial ownership of 2,552,536 shares of Sagimet Series A common stock.

What percentage of SGMT does the reported stake represent?

The reported position represents approximately 8.3% of the Series A common stock outstanding.

Is Woodline Partners claiming control of Sagimet (SGMT)?

No. The Schedule 13G filing includes a certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control.

Through which vehicle does Woodline hold the SGMT shares?

The shares are directly held by Woodline Master Fund LP, for which Woodline Partners LP serves as investment adviser.

What share count was used to calculate the 8.3% figure?

The percentage is calculated using an aggregate of approximately 30,674,855 shares of Series A common stock reported in the company’s quarterly report for the period ended March 31, 2025.
Sagimet Biosciences Inc.

NASDAQ:SGMT

SGMT Rankings

SGMT Latest News

SGMT Latest SEC Filings

SGMT Stock Data

207.81M
27.07M
9.81%
29.21%
7.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN MATEO